Free Trial

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Townsquare Capital LLC

Vertex Pharmaceuticals logo with Medical background

Key Points

  • Townsquare Capital LLC increased its holdings in Vertex Pharmaceuticals by 34.2%, owning 22,986 shares valued at approximately $11.1 million.
  • Multiple hedge funds are also investing in Vertex, with notable acquisitions totaling between $31,000 and $44,000 from firms such as Mascagni Wealth Management and Minot DeBlois Advisors.
  • Vertex Pharmaceuticals reported earnings of $4.52 per share, exceeding analyst expectations, and anticipates a projected EPS of 15.63 for the current year.
  • Need better tools to track Vertex Pharmaceuticals? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Townsquare Capital LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 34.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,986 shares of the pharmaceutical company's stock after buying an additional 5,859 shares during the quarter. Townsquare Capital LLC's holdings in Vertex Pharmaceuticals were worth $11,144,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Vertex Pharmaceuticals by 60,572.3% during the first quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company's stock valued at $1,175,722,000 after purchasing an additional 2,421,073 shares during the period. Capital World Investors lifted its position in shares of Vertex Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock valued at $11,406,667,000 after buying an additional 1,514,993 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Vertex Pharmaceuticals by 15.8% during the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after buying an additional 1,426,746 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 17.2% during the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company's stock valued at $2,454,373,000 after acquiring an additional 744,680 shares in the last quarter. Finally, Lazard Asset Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 6,487.2% during the fourth quarter. Lazard Asset Management LLC now owns 526,119 shares of the pharmaceutical company's stock valued at $211,867,000 after acquiring an additional 518,132 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their price target on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a report on Tuesday, August 5th. Cantor Fitzgerald decreased their target price on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Royal Bank Of Canada decreased their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Canaccord Genuity Group decreased their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating on the stock in a report on Wednesday, August 6th. Finally, Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Thirteen investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $497.10.

View Our Latest Stock Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Up 2.2%

VRTX stock traded up $7.92 during trading on Monday, hitting $374.46. 2,792,620 shares of the company's stock were exchanged, compared to its average volume of 2,128,999. The business has a 50-day moving average price of $450.77 and a two-hundred day moving average price of $465.95. The stock has a market capitalization of $96.01 billion, a price-to-earnings ratio of 26.77 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%. The company had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter in the previous year, the business earned ($12.83) earnings per share. The firm's revenue for the quarter was up 11.3% on a year-over-year basis. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines